![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB |
Preview |
PDF (Supplemental Information)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
| Item Type: | Article |
|---|---|
| Title: | Lipid mediator profiles predict response to therapy with an oral frankincense extract in relapsing-remitting multiple sclerosis |
| Creators Name: | Stürner, K.H., Werz, O., Koeberle, A., Otto, M., Pless, O., Leypoldt, F., Paul, F. and Heesen, C. |
| Abstract: | Lipid mediators (LMs) are a unique class of immunoregulatory signalling molecules and known to be affected by frankincense extracts. We performed LM profiling by metabololipidomics in plasma samples from 28 relapsing-remitting multiple sclerosis (RR-MS) patients who took a standardised frankincense extract (SFE) daily for eight months in a clinical phase IIa trial (NCT01450124) and in 28 age- and gender-matched healthy controls. Magnetic resonance imaging, immunological outcomes and serum neurofilament light chain levels were correlated to changes in the LM profiles of the RR-MS cohort. Eight out of 44 analysed LMs were significantly reduced during an eight-month treatment period by the SFE and seven of these eight significant LM derive from the 5-lipoxygenase (5-LO) pathway. Baseline levels of 12- and 15-LO products were elevated in patients who exhibited disease activity (EDA) during SFE treatment compared to no-evidence-of-disease-activity (NEDA) patients and could predict treatment response to the SFE in a prediction model at baseline. Oral treatment with an SFE significantly reduces 5-LO-derived LMs in RR-MS patients during an eight-month treatment period. Treatment response to an SFE, however, seems to be related to 12-,15-LO and cyclooxygenase product levels before SFE exposure. Further studies should confirm their biomarker potential in RR-MS and SFE treatment. |
| Keywords: | Biomarkers, Case-Control Studies, Electrospray Ionization Mass Spectrometry, Frankincense, Lipidomics, Lipids, Neurofilament Proteins, Oral Administration, Relapsing-Remitting Multiple Sclerosis, Unsaturated Fatty Acids |
| Source: | Scientific Reports |
| ISSN: | 2045-2322 |
| Publisher: | Nature Publishing Group |
| Volume: | 10 |
| Number: | 1 |
| Page Range: | 8776 |
| Date: | 29 May 2020 |
| Official Publication: | https://doi.org/10.1038/s41598-020-65215-6 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
